Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Roquefort Investments PLC ( (GB:ROQ) ) is now available.
Roquefort Therapeutics has agreed with Pleiades Pharma to extend the longstop dates for completing the sale of its wholly owned subsidiary Lyramid Pty Ltd and the out-licensing of its MK Cell patents to 31 December 2026. The extensions are intended to provide Pleiades with sufficient time to complete its ongoing fundraising with institutional and sovereign wealth investors in the Gulf Cooperation Council region, while all other terms of the agreements remain unchanged, preserving Roquefort’s strategic divestment and licensing plans.
The revised timetable reduces the immediate risk of these transactions lapsing due to fundraising delays and maintains Roquefort’s optionality around monetising Lyramid and the MK Cell intellectual property. For stakeholders, the move signals continued commitment to these deals, but also highlights dependence on Pleiades’ ability to secure capital in a challenging funding environment for biotech, potentially affecting the timing of any financial and operational benefits to Roquefort.
The most recent analyst rating on (GB:ROQ) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on Roquefort Investments PLC stock, see the GB:ROQ Stock Forecast page.
Spark’s Take on ROQ Stock
According to Spark, TipRanks’ AI Analyst, ROQ is a Neutral.
The score is primarily held back by weak financial fundamentals (pre-commercial revenue volatility, ongoing losses and cash burn). Technical indicators also point to a sustained downtrend. Low leverage on the balance sheet provides some support, but the negative P/E and lack of dividend yield limit valuation appeal.
To see Spark’s full report on ROQ stock, click here.
More about Roquefort Investments PLC
Roquefort Therapeutics plc is a Main Market listed biotechnology company on the London Stock Exchange that focuses on developing novel therapeutic technologies. The company operates through subsidiaries and partnerships to advance its pipeline, including assets such as Lyramid Pty Ltd and MK Cell patents, targeting opportunities in innovative drug development.
Average Trading Volume: 967,379
Technical Sentiment Signal: Sell
Current Market Cap: £1.68M
See more data about ROQ stock on TipRanks’ Stock Analysis page.